Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPFFR1 | Q9GZQ6 | 3/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272594 | 0.91 | CYP2D6 (0.49) | CYP2D6CYP3A4TSHROPRL1ALDH1A1 | |
| SCHEMBL2281012 | 0.87 | CYP2D6 (0.50) | CYP2D6CYP3A4TSHRALDH1A1NPFFR1 | |
| SCHEMBL14342254 | 0.84 | NPFFR1 (0.48) | CYP2D6CYP3A4TSHRALDH1A1NPFFR1 | |
| SCHEMBL2281940 | 0.83 | NPFFR1 (0.59) | CYP2D6CYP3A4TSHRALDH1A1NPFFR1 | |
| SCHEMBL14716038 | 0.82 | CYP2D6 (0.55) | CYP2D6CYP3A4TSHROPRL1ALDH1A1 | |
| SCHEMBL9381641 | 0.82 | CYP2D6 (0.46) | CYP2D6CYP3A4TSHRALDH1A1NPFFR1 | |
| SCHEMBL2277424 | 0.79 | CYP2D6 (0.51) | CYP2D6CYP3A4TSHRALDH1A1GAA | |
| SCHEMBL3937184 | 0.79 | NPFFR1 (0.66) | CYP2D6CYP3A4OPRL1ALDH1A1NPFFR1 | |
| SCHEMBL16684766 | 0.79 | OPRL1 (0.51) | CYP2D6CYP3A4TSHROPRL1ALDH1A1 | |
| SCHEMBL17082420 | 0.78 | CYP2D6 (0.53) | CYP2D6CYP3A4TSHROPRL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | CYP2D6 2287/4885CYP3A4 2784/4885TSHR 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.